Crispr Therapeutics AG

Crispr Therapeutics AG is a biotechnology company at the forefront of gene editing, specializing in the development of CRISPR/Cas9-based therapeutics. Founded in 2013 and headquartered in Zug, Switzerland, the company leverages the revolutionary CRISPR/Cas9 platform to precisely edit genomic DNA, aiming to create transformative gene-based medicines for a wide spectrum of serious diseases. Its pioneering portfolio includes approved therapies for blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia, notably the groundbreaking therapy developed in collaboration with Vertex Pharmaceuticals. Beyond hemoglobinopathies, Crispr Therapeutics AG is actively advancing clinical and preclinical programs in immuno-oncology, autoimmune diseases, type 1 diabetes, and cardiovascular conditions. The company is recognized for its robust pipeline, including innovative CAR T cell therapies for cancer and stem cell-derived therapies targeting metabolic disorders. Through an ongoing commitment to scientific excellence and collaborations with leading global partners, Crispr Therapeutics AG plays a vital role in shaping the future of precision medicine and gene therapy, offering novel solutions for both rare and common diseases.